Providing answers for your patients
Exclusive testing at Mayo Clinic Laboratories
Mayo Clinic Laboratories has a broad range of disease-specific tests that are clinically reinforced, cost-effective, and designed with patient outcomes in mind. Our unique approach to diagnoses includes tests that are not found anywhere else and helps find the right answers for patients, quickly.
From screening to therapeutic management, we offer comprehensive solutions for test ordering. We see thousands of patients every day — some with the most rare and complex cases — and continually innovate to find new ways to provide them answers. This ensures you and your patients have access to the most cutting-edge testing and technologies.
Our testing is backed by some of the world’s leading gastroenterology experts. Mayo Clinic subject matter experts provide ongoing consultative services and educational opportunities to strengthen your clinical practice, advance internal knowledge, and improve patient care.
Our clinically driven algorithmic approach ensures you’re administering the right test, for the right patient, at the right time. Together we can get patients more accurate answers, more quickly.
By the numbers
digestive disease specialists on staff — one of the largest such groups in the world
gastroenterology and GI surgery hospital in the nation by U.S. News & World Report
Results of our stand-alone 7AC4 serum screening not only provide physicians with a clearer understanding of the likelihood of BAM, but help to make informed decisions for patient follow-up, including the need for confirmatory fecal testing or the benefit of a trial bile acid sequestrant treatment.
Available exclusively at Mayo Clinic Laboratories and appropriate for all ages, our malabsorption evaluation panel includes assays carefully selected for their ability to quickly eliminate differential diagnosis and target the root cause of the gastrointestinal distress. Designed to expedite answers, our panel minimizes stress and optimizes patient outcomes.
Research conducted by Mayo Clinic on autonomic disease in an immune setting led to the discovery that immunotherapy can be beneficial for patients with autonomic disease. Our antibody testing can identify biomarkers that have indications for malignancies or point to the possibility of developing encephalopathy or seizures. It can also clarify the likelihood of an immune-therapy responsive condition that is unresponsive to intravenous immunoglobin and lead to more aggressive treatment.
We offer a noninvasive option for the molecular detection of H. pylori using a single fecal specimen. This testing: